Plain-English translation of NCT07454642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer medication called to see if it is safe and if it works against several types of advanced cancers. The study will start with small doses and gradually increase them to find the right dose for future patients. Researchers want to understand how the medication works in your body and what side effects it might cause.
Many advanced cancers do not respond well to existing treatments, and patients need new options. This medication is designed to target cancer cells in a new way, so researchers are testing whether it could help people whose cancers have stopped responding to standard care.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (through a vein) on a regular schedule — either once every 3 weeks or once every 2 weeks, depending on which group you are assigned to. In the first part of the study, the dose will gradually increase to find the safest and most effective dose. You will continue receiving the medication until your cancer gets worse, you experience unacceptable side effects, or you choose to stop. You will need regular blood tests and check-ins with the research team to monitor your health and how you are responding to treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States